96 related articles for article (PubMed ID: 18957720)
1. K-RAS and P53 mutations in association with COX-2 and hTERT expression and clinico-pathological status of NSCLC patients.
Strazisar M; Rott T; Glavac D
Dis Markers; 2008; 25(2):97-106. PubMed ID: 18957720
[TBL] [Abstract][Full Text] [Related]
2. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
3. Molecular analysis of p53 and K-ras in lung carcinomas of coal miners.
Sarkar FH; Li Y; Vallyathan V
Int J Mol Med; 2001 Oct; 8(4):453-9. PubMed ID: 11562787
[TBL] [Abstract][Full Text] [Related]
4. Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer.
Huang CL; Taki T; Adachi M; Konishi T; Higashiyama M; Kinoshita M; Hadama T; Miyake M
Int J Oncol; 1998 Mar; 12(3):553-63. PubMed ID: 9472092
[TBL] [Abstract][Full Text] [Related]
5. The expression of COX-2, hTERT, MDM2, LATS2 and S100A2 in different types of non-small cell lung cancer (NSCLC).
Strazisar M; Mlakar V; Glavac D
Cell Mol Biol Lett; 2009; 14(3):442-56. PubMed ID: 19238334
[TBL] [Abstract][Full Text] [Related]
6. Increased human telomerase reverse transcriptase (hTERT) mRNA expression but not telomerase activity is related to survival in curatively resected non-small cell lung cancer.
Metzger R; Vallbohmer D; Müller-Tidow C; Higashi H; Bollschweiler E; Warnecke-Eberz U; Brabender J; Baldus SE; Xi H; Berdel WE; Serve H; Hoelscher AH; Schneider PM
Anticancer Res; 2009 Apr; 29(4):1157-62. PubMed ID: 19414359
[TBL] [Abstract][Full Text] [Related]
7. Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology.
Ludovini V; Pistola L; Gregorc V; Floriani I; Rulli E; Piattoni S; Di Carlo L; Semeraro A; Darwish S; Tofanetti FR; Stocchi L; Mihaylova Z; Bellezza G; Del Sordo R; Daddi G; Crinò L; Tonato M
J Thorac Oncol; 2008 Apr; 3(4):365-73. PubMed ID: 18379354
[TBL] [Abstract][Full Text] [Related]
8. Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer.
Miura N; Nakamura H; Sato R; Tsukamoto T; Harada T; Takahashi S; Adachi Y; Shomori K; Sano A; Kishimoto Y; Ito H; Hasegawa J; Shiota G
Cancer Sci; 2006 Dec; 97(12):1366-73. PubMed ID: 17052260
[TBL] [Abstract][Full Text] [Related]
9. Clinical and prognostic value of hTERT mRNA expression in patients with non-small-cell lung cancer.
Zalewska-Ziob M; Dobija-Kubica K; Biernacki K; Adamek B; Kasperczyk J; Bruliński K; Ostrowska Z
Acta Biochim Pol; 2017; 64(4):641-646. PubMed ID: 29141053
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of Bcl-2 and mutations in p53 and K-ras in resected human non-small cell lung cancers.
Kitagawa Y; Wong F; Lo P; Elliott M; Verburgt LM; Hogg JC; Daya M
Am J Respir Cell Mol Biol; 1996 Jul; 15(1):45-54. PubMed ID: 8679221
[TBL] [Abstract][Full Text] [Related]
11. Detection of K-ras and p53 mutations in bronchoscopically obtained malignant and non-malignant tissue from patients with non-small cell lung cancer.
Lang SM; Stratakis DF; Freudling A; Ebelt K; Oduncu F; Hautmann H; Huber RM
Eur J Med Res; 2000 Aug; 5(8):341-6. PubMed ID: 10958767
[TBL] [Abstract][Full Text] [Related]
12. K-ras gene mutations in non-small cell lung cancer in Japanese.
Noda N; Matsuzoe D; Konno T; Kawahara K; Yamashita Y; Shirakusa T
Oncol Rep; 2001; 8(4):889-92. PubMed ID: 11410804
[TBL] [Abstract][Full Text] [Related]
13. The K-ras gene regulates vascular endothelial growth factor gene expression in non-small cell lung cancers.
Konishi T; Huang CL; Adachi M; Taki T; Inufusa H; Kodama K; Kohno N; Miyake M
Int J Oncol; 2000 Mar; 16(3):501-11. PubMed ID: 10675482
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers.
Grossi F; Loprevite M; Chiaramondia M; Ceppa P; Pera C; Ratto GB; Serrano J; Ferrara GB; Costa R; Boni L; Ardizzoni A
Eur J Cancer; 2003 Jun; 39(9):1242-50. PubMed ID: 12763212
[TBL] [Abstract][Full Text] [Related]
15. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma.
Moldvay J; Scheid P; Wild P; Nabil K; Siat J; Borrelly J; Marie B; Farré G; Labib T; Pottier G; Sesboüé R; Bronner C; Vignaud JM; Martinet Y; Martinet N
Clin Cancer Res; 2000 Mar; 6(3):1125-34. PubMed ID: 10741743
[TBL] [Abstract][Full Text] [Related]
16. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.
Beau-Faller M; Ruppert AM; Voegeli AC; Neuville A; Meyer N; Guerin E; Legrain M; Mennecier B; Wihlm JM; Massard G; Quoix E; Oudet P; Gaub MP
J Thorac Oncol; 2008 Apr; 3(4):331-9. PubMed ID: 18379349
[TBL] [Abstract][Full Text] [Related]
17. Detection of activated K-ras in non-small cell lung cancer by membrane array: a comparison with direct sequencing.
Chong IW; Chang MY; Sheu CC; Wang CY; Hwang JJ; Huang MS; Lin SR
Oncol Rep; 2007 Jul; 18(1):17-24. PubMed ID: 17549340
[TBL] [Abstract][Full Text] [Related]
18. Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer.
Sirera R; Bremnes RM; Cabrera A; Jantus-Lewintre E; Sanmartín E; Blasco A; Del Pozo N; Rosell R; Guijarro R; Galbis J; Sánchez JJ; Camps C
J Thorac Oncol; 2011 Feb; 6(2):286-90. PubMed ID: 21252717
[TBL] [Abstract][Full Text] [Related]
19. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
[TBL] [Abstract][Full Text] [Related]
20. A novel molecular staging protocol for non-small cell lung cancer.
Miyake M; Adachi M; Huang C; Higashiyama M; Kodama K; Taki T
Oncogene; 1999 Apr; 18(14):2397-404. PubMed ID: 10327061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
